| INTRODUCTION
Nine of twelve study sites also participated in a pilot laboratory project where they randomly selected specimens for sequencing of at least the gene segment coding for the haemagglutinin, in order to compute a representative VE estimate against the influenza A(H1N1) pdm09 6B.1 genetic group.
| METHODS
Twelve European study sites located in Croatia, France, Germany, Hungary, Ireland, Italy, Poland, Portugal, Romania, Spain, Sweden and the Netherlands participated in the test-negative 2015/16 multicentre case-control study. The methods have been described previously [2] [3] [4] Background: During the 2015/16 influenza season in Europe, the cocirculating influenza viruses were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from the B/Yamagata component in the trivalent influenza vaccine.
Methods:
We used the test-negative design in a multicentre case-control study in twelve European countries to measure 2015/16 influenza vaccine effectiveness (VE) against medically attended influenza-like illness (ILI) laboratory-confirmed as influenza. General practitioners swabbed a systematic sample of consulting ILI patients and a random sample of influenza-positive swabs was sequenced. We calculated adjusted VE against influenza A(H1N1)pdm09, A(H1N1)pdm09 genetic group 6B.1 and influenza B overall and by age group.
Results: We included 11 430 ILI patients, of which 2272 were influenza A(H1N1) pdm09 and 2901 were influenza B cases. Overall VE against influenza A(H1N1)pdm09 was 32.9% (95% CI: 15.5-46.7). Among those aged 0-14, 15-64 and ≥65 years, VE against A(H1N1)pdm09 was 31.9% (95% CI: −32.3 to 65.0), 41.4% (95% CI: 20.5-56.7) and 13.2% (95% CI: −38.0 to 45.3), respectively. Overall VE against influenza A(H1N1) pdm09 genetic group 6B.1 was 32.8% (95% CI: −4.1 to 56.7). Among those aged 0-14, 15-64 and ≥65 years, VE against influenza B was −47.6% (95% CI: −124.9 to 3.1), 27 .3% (95% CI: −4.6 to 49.4) and 9.3% (95% CI: −44.1 to 42.9), respectively.
Conclusions:
Vaccine effectiveness (VE) against influenza A(H1N1)pdm09 and its genetic group 6B.1 was moderate in children and adults, and low among individuals ≥65 years. Vaccine effectiveness (VE) against influenza B was low and heterogeneous among age groups. More information on effects of previous vaccination and previous infection is needed to understand the VE results against influenza B in the context of a mismatched vaccine.
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and are based on the ECDC generic case-control study protocol and the I-MOVE+ protocol. 5, 6 Participating practitioners interviewed and collected nasopharyngeal or combined naso-and oropharyngeal specimens from a systematic sample of consenting patients seeking medical attention for influenza-like illness (ILI). In Hungary, only patients aged 18 years and older and in Croatia only patients aged 65 years and older were eligible. Practitioners collected in a standardised report form information including symptoms, date of onset and swabbing, 2015/16 seasonal vaccination status, date of influenza vaccination and vaccine product, prior (2014/15) seasonal vaccination status, sex, age and presence of chronic medical conditions in the past 12 months.
Seven study sites included a question on belonging to the target group for vaccination. In France, Germany, Poland, Portugal and Sweden, the target group was defined from patients' information on age, chronic conditions and pregnancy. Additionally, in Portugal, being a health professional or carer and a cohabitant or carer of a patient at risk aged less than 6 months and in Poland, belonging to an occupational risk group (eg, healthcare worker), defined the target group.
In the pooled analysis, we included patients meeting the European Union ILI case definition, 7 swabbed within 7 days of symptom onset, and who had not received antivirals in the 14 days prior to swabbing.
A case of confirmed influenza was an ILI patient who was swabbed and tested positive for influenza virus using real-time reverse-transcription polymerase chain reaction (RT-PCR). Controls were ILI patients who tested negative for any influenza virus using
RT-PCR.
We defined a person as vaccinated if he or she had received at least one dose of a 2015/16 seasonal influenza vaccine more than 14 days before ILI symptom onset. Those vaccinated less than 15 days before ILI onset were excluded. All other patients were classified as unvaccinated.
For each study site, we included ILI patients presenting more than 14 days after the start of national or regional influenza vaccination campaigns and we excluded controls presenting before the onset week of the first influenza type/subtype-specific case. ILI patients presenting in weeks of onset after two or more consecutive weeks of no cases and influenza A cases that were not further subtyped were also excluded from the analysis.
For each study site, we computed the odds ratio (OR) of being vaccinated in cases vs controls. We conducted a complete analysis excluding patients with missing values for any of the variables in the model measuring adjusted VE. Using Cochran's Q-test and the I 2 index, we tested the heterogeneity between study sites. 8 We estimated the pooled type/subtype influenza VE as (1 minus the OR)*100 using a one-stage model with study site as a fixed effect.
Using a logistic regression model, we calculated VE including potential confounding factors: date of symptom onset (modelled as a restricted cubic spline with 4 knots where sample size allowed), age (modelled as a restricted cubic spline with 4 knots or age groups depending on the analysis), sex and presence of at least one chronic medical condition (including pregnancy and obesity where available).
We used the one in ten rule of predictor degrees of freedom to events to determine the maximum number of covariates to include in analyses with low sample sizes in order to avoid overfitting the model. We weighted the genetic group-specific VE analysis using the reciprocal of the sequencing sampling fraction for each time period and study site and used robust standard errors.
Data management and statistical analyses were carried out using Stata 14 (StataCorp. 2015. College Station, TX, USA).
| RESULTS
The cases and 6.3% among influenza B cases ( Table 1 ).
The median age of influenza A(H1N1)pdm09 cases was 35 years, of controls 29 years and of influenza B cases 12 years (Table 2) . 
| Influenza A(H1N1)pdm09
Statistical heterogeneity between VE estimates against influenza A(H1N1)pdm09 by study site was low overall (among all ages) and among those aged 15-64 years (I 2 index 0% and 10%, respectively).
Due to small sample sizes, it was not possible to estimate heterogeneity among other age groups.
The adjusted VE in the total population (all ages) against influenza A(H1N1)pdm09 was 32.9% (95% CI: 15.5-46.7) ( Number of records received for pooled analysis: 14 294 Excluding records: Table 2 ). The sample size was too small to calculate VE for those aged 65 years and older.
| Influenza B
The I 2 index for heterogeneity between VE estimates against influenza B by study site was 56% among all ages and 0% among those aged 15-64 years. Due to small sample size, it was not possible to estimate heterogeneity among those aged 65 years and older. Among children, we could measure the I 2 between three countries (DE, FR and IT; in all other countries, less than 5 children were vaccinated), which was 0%.
The adjusted VE against influenza B was −47.6% (95% CI: −124.9 to 3.1) among the 0-to 14-year-olds and 27.3% (95% CI: −4.6 to 49.4) among the 15-to 64-year-olds ( Adjusted by age and study site only.
f Due to heterogeneity of VE estimates against influenza B between age groups, no "all ages" estimate against influenza B was attempted.
g Adjusted by time and study site only.
T A B L E 2 (Continued)
| DISCUSSION
The 2015/16 influenza VE against medically attended ILI due to influenza A(H1N1)pmd09 in the I-MOVE/I-MOVE+ multicentre casecontrol study in Europe ranged from 13.2% to 55.5% in the total and target population, depending on age group. There was a very low VE or no protective effect against influenza B among the 0-to 14-year-olds and VE among the 15-to 64-year-olds among the total and target population ranged from 27.3% to 38.4%. The VE against influenza B was very low or may have conferred no protection among children and was low to moderate among 15-to 64-year-olds. The differences in VE between age groups were large (P < .001). In the context of this effect modification and differential age distributions between studies, due to different healthcare-seeking behaviours and practitioners included in the study (France, Italy, Germany and Spain include paediatricians in the study), providing a VE among all ages was not appropriate. The age-specific effect modification and differential age distribution may explain in part why the heterogeneity of study site-specific estimates among all ages was moderate to high (I 2 = 55.9%).
In the UK and the USA, the 2015/16 VE against influenza B among children was higher than in the I-MOVE/I-MOVE+ multicentre T A B L E 3 Influenza A(H1N1)pdm09, influenza B/Yamagata and influenza B/Victoria viruses characterised by clade and study site, study sites participating in the laboratory pilot study, I-MOVE multicentre case-control study, case-control study. The VE was 56.3% in the UK among those children receiving the (predominantly trivalent) inactivated injectable vaccine, and in the USA, the VE was 64% against B/Yamagata and 56% against B/Victoria among those children receiving the (predominantly quadrivalent) inactivated injectable vaccine. 14, 17 A low VE among children was seen in Finland receiving the (predominantly trivalent) inactivated injectable vaccine (−1%). 22 In the USA, there is a universal vaccination recommendation, and in the UK and Finland, vaccine is recommended in certain age groups in children. However, in the countries participating in the I-MOVE/I-MOVE+ multicentre case-control study, vaccine is recommended only to children with chronic conditions, with the exception of Poland where vaccination is recommended among those aged 6 months to 18 years. [23] [24] [25] The season. 16, 17 In the 2015/16 season, the circulating strains were antigenically distinct from the strain selected for the influenza B component in the trivalent influenza vaccine. Nevertheless, there was VE of 27.3%
among the 15-to 64-year-olds. Varying levels of cross-protection have been reported previously. [26] [27] [28] In the 2015/16 season, our VE point estimates are less than 10% among those aged 0-14 years and those aged 65 years and above. Among older adults and children, the differences observed in VE in a season of mismatch between the vaccine and circulating strains may be explained by a combination of immune system properties specific to children and the elderly, as well as by the role of previous vaccinations and previous infections.
The VE point estimate was higher for subunit vaccine than for split virion vaccine among children, but precision was low. Both estimates were low, indicating that the low VE was not due to a vaccine typespecific issue. Among 15-to 64-year-olds, split virion VE point estimate was higher than subunit vaccine, but again precision was low. 
